Bio-Techne Q2 FY2026 Revenue Flat at $295.9M, Adjusted EPS Jumps to $0.46
Bio-Techne posted Q2 FY2026 revenue of $295.9 million, flat year-over-year, with organic growth neutral and a 2% favorable FX impact offset by a 2% held-for-sale drag. GAAP EPS increased to $0.24 and adjusted EPS rose to $0.46 from $0.42, while adjusted operating margin expanded by 100 basis points to 31.1%.
1. Citigroup Stock Upgrade Reflects Bullish Analyst Outlook
On February 4, Citigroup upgraded Bio-Techne’s shares to a Buy rating and raised its 12-month price target by 14% to $80, underscoring expectations for above-market growth. The firm cited the company’s differentiated life-sciences portfolio and sustained demand in drug-development reagents as key drivers. This upgrade marks the second positive revision from a major Wall Street bank in the past six months and follows three consecutive quarters of double-digit growth in the large-pharma end market, according to management commentary.
2. Q2 FY2026 Results Show Margin Expansion Despite Flat Organic Revenue
In the quarter ended December 31, Bio-Techne reported revenue of $295.9 million, in line with the prior year on both a reported and organic basis. GAAP operating income rose 15% to $54.5 million, driving operating margin to 18.4% from 16.0% a year earlier. On a non-GAAP basis, adjusted EPS climbed 10% to $0.46, beating the consensus by 7%. Adjusted operating margin expanded by 100 basis points to 31.1%, reflecting productivity initiatives and the Exosome Diagnostics divestiture. Regional performance was led by China/APAC, which delivered its third straight quarter of growth, while large-pharma sales achieved four consecutive quarters of double-digit gains.
3. Segment Performance Highlights Resilient Protein Sciences Unit
The Protein Sciences segment generated net sales of $215.1 million, up 2% year-over-year, with foreign-exchange tailwinds offsetting a 1% decline in organic revenues. Operating margin in the segment ended at 39.3%, down from 41.2% due to product-mix headwinds. The Diagnostics & Spatial Biology segment recorded net sales of $81.2 million, down 4%, but achieved a 10.4% operating margin versus 3.9% last year, driven by the Exosome Diagnostics carve-out and cost-containment measures.
4. Board Declares Quarterly Dividend to Strengthen Income Profile
Bio-Techne’s board approved a quarterly dividend of $0.08 per share, payable February 27, to shareholders of record on February 16. This marks the eighth consecutive quarterly payout, reflecting management’s commitment to returning cash while maintaining flexibility for strategic R&D investments. The dividend yield now stands above the sector average, providing an additional catalyst for income-oriented investors.